INCY vs PATH · P/E 14, rev $4.24B vs P/E 19, rev $1.61B
Incyte Corporation (INCY) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported INCY revenue for 2024-12-31 was $4.24B. Net income was $32.6M. Revenue was up 14.8% from 2023-12-31 to 2024-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the INCY and PATH stock pages for the full models.
Not investment advice.